Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-Assisted Psychotherapy vs Ketamine Alone for Depression
NCT06559826Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jan 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06559826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559826.